
Kliniska studier vid Tema Cancer
–Studier öppna för inklusion inom Fas 1-enheten–
Nedan listas de studier som är öppna för patientinklusion. Vidare visas ansvarig prövare, forskningssjuksköterska och aktuell inklusion. Listan uppdateras minst en gång i veckan. -Längst ner finns förklaring till de olika kolumnerna.
Nr | Namn | Fas |
Startdatum | Ansvarig prövare |
06/09 |
SECAR-studien. Part I: A study of MTD of Sodium selenite in patients with advanced carcinoma. A phase I study.Amendment 4: continuous treatment |
1 |
2007-02-01 |
Mattias Hedman |
16/27 |
MASTIFF. MASTIFF MTH1, A phase I, Study on Tumors Inhibition, First in human, First in class |
1 |
2017-01-20 |
Jeffrey Yachnin |
17/09 |
BoB. Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumors |
2 |
2019-06-18 |
Luigi de Petris |
18/030 |
PSFF STUDIE- Blodburna vävnadsprov. Screening-program med blodburna vävnadsprov för patienter med avancerad cancer - PSFF studie |
Ej tillä |
2019-06-12 |
Jeffrey Yachnin |
18/031 |
Keynote-587. A multicenter, open label, phase III extension trial to study the long-term safety and efficacy in participants with advanced tumors who are currently on treatment or in follow-up in a pembrolizumab trial. |
3 |
2018-11-20 |
Jeffrey Yachnin |
19/062 |
BI-1206-03 MonKey. Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD1 or Anti-PDL1 Antibodies |
1-2 |
2020-11-15 |
Jeffrey Yachnin |
19/095 |
Spencer-study. A phaSe 1/2 trial of EO2401, a novel microbial-derived Peptide therapeutic vaccine, in combination with PD-1 check point blockadE, for treatment of patients with locally advaNced or metastatic adrenocortical Carcinoma, or malignant phEochromocytoma/paRaganglioma |
1-2 |
2021-05-20 |
Jeffrey Yachnin |
20/004 |
Navigate. A Phase II Basket Study of the Oral TRK Inhibitor Larotrectinib in Subjects with NTRKFusion-Positive Tumours |
2 |
2020-12-01 |
Jeffrey Yachnin |
20/041 |
BIKUPAN (19-BI-1808-01). Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Malignancies |
1-2 |
2022-01-27 |
Jeffrey Yachnin |
21/003 |
ONCORELLA-1 (ONC001-CL-001). A phase I/II, open label, single arm study on safety, tolerability and anti-tumour efficacy of orellanine treatment in patients with metastatic clear-cell or papillary renal cell carcinoma |
1 |
2022-02-08 |
Jeffrey Yachnin |
21/010 |
MCLA-128-CL01 eNRGy. A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors |
1-2 |
2021-11-18 |
Jeffrey Yachnin |
21/043 |
CCS1477-02. An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy in patients with hematological malignancies |
1-2 |
2022-02-07 |
Maria Creignou |
21/050 |
FIRST (RLY-4008-101). A First-in-Human Study of Highly Selective FGFR2 Inhibitor,RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors |
1 |
2021-09-23 |
Jeffrey Yachnin |
21/051 |
iPCM. iPCM - implementation of Personalised Cancer Medicine |
Ej tillä |
2021-09-24 |
Jeffrey Yachnin |
21/087 |
Cloudin-6 BNT211-01. Phase I/IIa, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-positive relapsed or refractory advanced solid tumors |
1-2 |
2023-05-28 |
Stephan Mielke |
22/036 |
CERTIS1. A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination with Anti-cancer Agents in Patientswith Advanced Solid Malignancies (CERTIS1) |
1-2 |
2023-01-12 |
Theodoros Foukakis |
22/046 |
NeoGap (NEOGAP-CRC-01). A First-In-Human, Phase I/IIa Trial of the novel T cell Immunotherapy pTTL in Patients with Advanced Colorectal Cancer |
1 |
2023-03-16 |
Maximilian Kordes |
22/048 |
ALPHAVILLE (SGNALPV-001). Phase 1 Study of SGN-ALPV in Advanced Solid Tumors |
1 |
2023-04-21 |
Jeffrey Yachnin |
22/063 |
FORE (F8394-201). A Phase 2 Master Protocol to assess the efficacy and safetyof FORE8394, an inhibitor of BRAF class 1 and class 2alterations, in participants with cancer harboring BRAFalterations |
2 |
2023-06-29 |
Jeffrey Yachnin |
22/067 |
BIWAC (BI 1403-0001- Brightline). A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 in patients with advanced or metastatic solid tumors |
1 |
2023-03-16 |
Christina Linder Stragliotto |
Nr: Forskningsrådets nummer.
Namn: Studiens kortnamn följt av protokollets hela titel.
Fas: Kan vara Fas 1, 2, 3 eller Pilot, kombinationer av dessa, eller Ej tillämpligt.
Startdatum: Vanligen datum för startmöte eller
liknande.
Ansvarig prövare: Den läkare som är ansvarig
för studien inom Tema Cancer.
Ansvarig forskn.sköt: Den forskningssjuksköterska
som är ansvarig.
CKC, Tema Cancer, Karolinska universitetssjukhuset 08.12.2023